decrease platelet aggregation and prevent thrombus formation.
In contrast to the use of blood pressure and lipid lowering drugs and anticoagulants, where biomarkers (blood pressure, blood lipids, and coagulation screen) can be used to adjust treatment, antiplatelet drugs
are given in a "fire and forget" manner since there are no validated, widely available, or inexpensive tests of platelet function that measure platelet activity reliably and reproducibly, correlate with recurrent events, and can be measured remotely from a dedicated platelet laboratory.
The aim of this study was to examine the transient events of concurrent use of antiplatelet drugs
with a set of prespecified CMs and its association with hospitalization due to major bleeding events.
Chen, "Antiplatelet drug
resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population," Journal of Neurology, vol.
conducted a prospective clinical study by performing simple dental extractions on 43 patients taking 2 anti-platelet drugs, mostly aspirin and clopidogrel and 117 patients taking a single antiplatelet drug
in the form of aspirin, clopidogrel and ticlopidine.
Due to antiplatelet drug
the density of blood gets thinner and leads to the motion of fluid freely inside the arteries.
Despite the use of these drugs, ischemic events recur in considerable number of patients due to development of antiplatelet drug
CILOSTAZOL (PLETAL): is an antiplatelet drug
with vasodilatation properties; it is approved for use in intermittent claudication where there is no pain at rest and no tissue necrosis.
However, there are more than 90 other metabolic pathways leading to platelet aggregation that are independent of arachidonic acid and therefore not inhibited by aspirin, hence, therefore the need for inhibition of other platelet activation pathways has led to the development of various other antiplatelet drugs
. An improved understanding of the underlying mechanisms involved in thrombogenesis has paved the way for further development of newer antiplatelet drug
Aspirin is an effective antiplatelet drug
for preventing thrombo-embolic vascular events.
As an example, antiinflammatory and antiplatelet drug
aspirin, one of the most widely prescribed drugs on the market, is a plant-derived compound originally from willow and other salicylate-rich plants.
Aspirin combined with the antiplatelet drug
clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination carries a greater risk of gastrointestinal bleeding, according to results of a trial funded by the National Institutes of Health.